EMAIL THIS PAGE TO A FRIEND

The American journal of tropical medicine and hygiene

Tafenoquine for the treatment of recurrent Plasmodium vivax malaria.


PMID 17360873

Abstract

Tafenoquine was used to treat Plasmodium vivax malaria cases who had previously failed treatment with chloroquine and primaquine. Chloroquine was followed by a loading dose of tafenoquine (200 mg base/day for 3 days) and 200 mg a week was given for 8 weeks. One of 27 treated patients relapsed after 6 months of observation. A standard course of chloroquine administered with 8 weeks of tafenoquine may be more effective than chloroquine with primaquine (22.5 mg/day for 14 days) in preventing additional P. vivax relapses. Larger studies are required to optimize the combination, but our findings suggest that an extended use of tafenoquine may be required to prevent relapses of primaquine-tolerant strains of P. vivax malaria.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SML0396
Tafenoquine succinate, ≥95% (HPLC)
C24H28F3N3O3 · C4H6O4